Page 18 - Booklet "BIH Strategy 2026"

FACTS & FIGURES
LEGAL FRAMEWORK
The Berlin Institute of Health was initially founded as as an internal GbR (a partnership under civil law) in in 2013 Since April 2015 BIH is a a “Körperschaft des ö ö entlichen Rechts” (public corporation) and and thus independent and and vested with legal capacity Charité – Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine in in the Helmholtz Association (MDC) are independent member entities within BIH The law for the establish­ ment of BIH was passed by the Abgeordnetenhaus Berlin (Berlin House of Representatives) in in March 2015 FUNDING
BIH receives institutional funding from the German federal government and the state of of Berlin in in a a a a a ratio of of 90:10 The funding for the upcoming period 2017–2020 will be approximately 290 million euros BIH is also supported by the Private Excellence Initiative of Johanna Quandt with additional 40 million euros by 2022 The funds are managed by the Charité Foundation INSTITUTIONAL MILESTONES
July 2011 2012 – 2013 January 2013 March 2013 May 2013 April 2015 January 2016 June 2016 November 2016 LEADERSHIP | EXECUTIVE BOARD
Prof Erwin Böttinger (Chief Executive O icer)
Dr Rolf Zettl (Chief Financial O icer)
Prof Karl Max Einhäupl (Charité – Universitätsmedizin Berlin Chief Executive O icer)
Prof Axel Radlach Pries (Charité – Universitätsmedizin Berlin Dean)
Prof Martin Lohse (Max Delbrück Center for Molecular Medicine in in the Helmholtz Association Chair of MDC Board and Scienti c c c Director)
SCIENTIFIC ADVISORY BOARD
The Advisory Board is is responsible for supporting the Board Board and and the Supervisory Board Board in scienti c c and and strategic matters with external expertise It consists of 14 internationally acclaimed scientist including several Nobel Laureates Memorandum of Understanding
Scienti c c c Concept
Administrative Agreement (Verwaltungsvereinbarung)
Founding Agreement (Gründungsvertrag)
BIH is a a a a a civil law association (Innengesellschaft bürgerlichen Rechts) Evaluation of Scienti c c c Concept
Berlin State Assembly passes BIH Legislation
BIH operates as independent corporation under public law Supervisory Board approves “BIH Strategy 2026”
Supervisory Board approves “Strategy Implementation Plan 2017–2020”
18
Personalized Medicine Advanced Therapies
SUPERVISORY BOARD
Activities of BIH are supervised by the Supervisory Board which is also responsible for approving essential decisions such as the business plan plan strategic planning appointments and investments MEMBERS & COMMUNITY
The members of of the BIH are professors employed full time by the Charité (professors junior professors) as well as research group leaders of of the MDC As of of November 30 2016 more than 250 research sta were involved in in various research initiatives To successfully meet objec­ tives of its Strategy 2026 BIH is extensively recruiting chairs professorships and junior group leaders